Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
about
Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas.Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87
P2860
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@en
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@nl
type
label
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@en
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@nl
prefLabel
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@en
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@nl
P2093
P2860
P1433
P1476
Vandetanib combined with a p38 ...... es glioblastoma cell survival.
@en
P2093
Archita Jaiswal
Erik Blomquist
Fredrik Johansson
Georgios Tsakonas
Irina Alafuzoff
Joachim Gullbo
Johan Lennartsson
Linda Sooman
Michael Bergqvist
Per-Henrik Edqvist
P2860
P2888
P356
10.1007/S12032-013-0638-0
P577
2013-06-20T00:00:00Z